July 26-30, Amsterdam, Netherlands
Scientific Sessions
On This Page:
To search a full listing of sessions available at this year’s conference, use the AAIC Interactive Program Guide.
10:30 - 11:15 a.m.
Association Welcome
11:15 - 11:45 a.m.
Understanding the Earliest Phases of Alzheimer’s Disease
Johns Hopkins University School of Medicine, USA
Theme: Therapeutics
Session: PL-01-02
10:30 - 11 a.m.
Sleep, Brain and Cognition
University of California, Irvine, USA
Theme: Therapeutics
Session: PL-02-01
11 - 11:30 a.m.
Alzheimer’s Disease Blood-Based Biomarkers and AD Control
Seoul National University, South Korea
Theme: Diagnosis and Prognosis
Session: PL-02-02
10:30 - 11 a.m.
Inge Grundke-Iqbal Award for Alzheimer’s Research: Neurotoxic Reactive Astrocytes Are Induced by Activated Microglia
NYU School of Medicine, USA
Theme: Basic and Translational Science
Session: PL-03-01
11 - 11:30 a.m.
The Epidemiology of Diversity and Dementia
University of California, Davis, USA
Theme: Public Health and Psychosocial
Session: PL-03-02
10:30 - 11 a.m.
Imaging Neurodegeneration With MRI: What Is New?
University of Pennsylvania Memory Center, USA
Theme: Diagnosis and Prognosis
Session: PL-04-01
11 - 11:30 a.m.
The Cellular Phase of Alzheimer’s Disease
University College London, United Kingdom; University of Leuven, Belgium
Theme: Basic and Translational Science
Session: PL-04-02
10:30 - 11 a.m.
Microglia in Neurodegenerative Conditions
Washington University in St. Louis, USA
Theme: Basic and Translational Science
Session: PL-05-01
11 - 11:30 a.m.
Precision Medicine, Population Neuroscience and Comprehensive Care: Partners to Develop and Deliver Effective Prevention and Treatments for Dementia
The University of Texas Health Science Center at San Antonio, USA
Theme: Public Health & Psychosocial
Session: PL-05-02
Symposium Sessions
-
Disparities in Access to Dementia Care and Prevention [S1-01]
8 - 9:30 a.m.
Theme: Public Health and Psychosocial
PRESENTATIONS
SPEAKERS
Dementia Prevention Programs in Urban and Regional Aboriginal Communities in Australia [S1-01-01]
Kylie Radford
University of New South Wales, Australia
Health Literacy and Access to Dementia Care [S1-01-02]
Jennifer Lingler
University of Pittsburgh, USA
Improving the Lives of People with Dementia - The OECD Perspective [S1-01-03]
Elina Suzuki
Organization for Economic Co-operation and Development, France
Dementia As Access Barrier in Palliative Care [S1-01-04]
Jenny T. van der Steen
Leiden University Medical Center, Leiden, Netherlands
-
“Rare Variants” And Their Role In Genetic Etiology And Disease [S1-02]
8 - 9:30 a.m.
Theme: Basic and Translational Science
PRESENTATIONS
SPEAKERS
Clustering of Rare Variants in Alzheimer Disease and Related Disorders in the Colombian Population: A Genomic Study [S1-02-01]
Ken Kosik
University of California, USA
The Potential Contribution of Rare Variants to Neurodegenerative Brain Dementia [S1-02-02]
Gary Beecham
The Dr. John T. Macdonald Foundation Department of Human Genetics, University of Miami Miller School of Medicine, USA
Whole-Exome Sequencing in 20,197 Persons for Rare Variants in Alzheimer's Disease [S1-02-03]
Richard Mayeux
Columbia University Medical Center, USA
High-Throughput Identification of Noncoding Functional SNPs [S1-02-04]
Gang Li
University of Pittsburgh School of Medicine, USA
-
PET and CSF Markers of Neuroinflammation [S2-01]
8 - 9:30 a.m.
Theme: Diagnosis and Prognosis
PRESENTATIONS
SPEAKERS
PET Markers of Microglia [S2-01-01]
Robert Innis
National Institute of Mental Health, USA
PET Markers of Astrocytes [S2-01-02]
Elena Rodriguez-Vieitez
Karolinska Institute, Sweden
Neuroinflammation: CSF Perspective [S2-01-03]
Shorena Janelidze
Lund University, Sweden
Fluid Biomarkers of Neuroinflammation [S2-01-04]
Charlotte Teunissen
VU University Medical Center, Netherlands
-
Precision Medicine [S2-02]
8 - 9:30 a.m.
Theme: Therapeutics
PRESENTATIONS
SPEAKERS
Precision Medicine Model for Targeted NSAID Therapy in AD [S2-02-01]
Sid O'Bryant
University of North Texas Health Science Center, USA
PPAR-Gamma [S2-02-02]
Michael Heneka
German Center for Neurodegenerative Diseases (DZNE), Germany
Insulin-Resistant Sub-Typing [S2-02-03]
Suzanne Craft
Wake Forest School of Medicine, USA
Subtyping of Clinical Subjects through Exosome Analyses [S2-02-04]
Dimitrios Kapogiannis
National Institute on Aging/National Institutes of Health (NIA/NIH), USA
-
Overlapping AD Pathologies and their Influence on Disease Phenotypes [S3-01]
8 - 9:30 a.m.
Theme: Diagnosis and Prognosis
PRESENTATIONS
SPEAKERS
Alzheimer’s and Vascular Disease: A Pathobiological Perspective [S3-01-01]
Costantino Iadecola
Weill Cornell Medicine, USA
Alzheimer’s Disease and Subcortical Vascular Cognitive Impairment (SVCI): Biomarker Perspective [S3-01-02]
Duk Na
Samsung Medical Center; Sungkyunkwan University School of Medicine, Korea, Republic of Korea (South)
Alzheimer’s and Lewy Body Disease: Pathologic Perspective [S3-01-03]
David Irwin
University of Pennsylvania, USA
Alzheimer’s and Lewy Body Disease: Biomarker Perspective [S3-01-04]
Evelien Lemstra
Amsterdam University Medical Centers, Netherlands
-
Responder Analyses Leading to Hypothesis Generation for Prospective Study Designs [S3-02]
8 - 9:30 a.m.
Theme: Therapeutics
PRESENTATIONS
SPEAKERS
Statistical Challenges With Responder Analysis in Exploratory Settings [S3-02-01]
Suzanne Hendrix
Pentara Corporation, USA
Multi-Crossover Randomized Control Design Approaches Based on Analyses of Responder/Non-Responder Outcomes [S3-02-02]
Steven Arnold Massachusetts General Hospital, USA; Harvard Medical School, USA
To be announced.
Statistical Considerations for Efficient Designs within a Platform Trial Approach [S3-02-03]
Karen Messer
University of California San Diego, USA
Determining Whether Identification of a Responder Sub-Group Is Truly Hypothesis Generating [S3-02-04]
Eric Siemers
Siemers Integration LLC, USA
-
National Dementia Registries: Quality Control and Recruitment of Research Participants [S4-01]
8 - 9:30 a.m.
Theme: Public Health and Psychosocial
PRESENTATIONS
SPEAKERS
Identifying Elders at Risk for Cognitive Decline Using the Brain Health Registry (BHR) [S4-01-01]
Michael Weiner
University of California, San Francisco, USA
The Dutch Brain Health Registry for Recruitment of Research Participants [S4-01-02]
Marissa Zwan
VU University Medical Center, Netherlands
Swedish Clinical Quality Registry for Dementia [S4-01-03]
Dorota Religa
Karolinska Institute, Sweden
The Australian Dementia Network (ADNet) Clinical Quality Registry [S4-01-04]
Stephanie Ward
Monash University, Australia
-
Delirium in Dementia: A Translational Aspect [S5-01]
8:30 - 10 a.m.
Theme: Basic and Translational Science
PRESENTATIONS
SPEAKERS
Description and Impact of Delirium on Dementia [S5-01-01]
Daniel Davis
University College London, United Kingdom
Biomarkers in Delirium [S5-01-02]
Gideon Caplan
University of New South Wales, Australia
Neurobiology of Delirium and Its Intersection with Dementia: Insights from Animal Models [S5-01-03]
Colm Cunningham
Trinity College Dublin, Ireland
Systemic Inflammation Signaling to the Brain [S5-01-04]
Roosmarijn Vandenbroucke
Ghent University, Belgium
-
Focused Topic Session: Review of Developments in Disease Modifying Strategies for Alzheimer’s Disease: A Focus on Anti-Amyloid Strategies [FTS5-01]
8:30 - 10 a.m.
PRESENTATIONS
SPEAKERS
Immunotherapy in Alzheimer Disease: Mechanisms of Monoclonal Antibodies in Development [FTS5-01-01]
Christopher van Dyck
Yale School of Medicine, USA
Correlating Cognitive Outcomes with Patient Specific Biomarkers in Alzheimer’s Disease [FTS5-01-02]
Jose Luis Molinuevo
ICN Hospital Clinic i Universitari, Spain
A Pharmacokinetic / Pharmacodynamic Evaluation of Imaging Biomarkers of Alzheimer's Disease [FTS5-01-03]
Tammie Benzinger
Knight Alzheimer's Disease Research Center, USA
The Amyloid Hypothesis: Latest Update in the Context of Recent Trial Evidence [FTS5-01-04]
Reisa Sperling
Brigham and Women's Hospital, USA
Panel Discussion [FTS5-01-05]
Presentation Speakers
lg > 992px
md > 768px
sm < 767px
xs
Join the Conversation #AAIC19